Several brokerages have updated their recommendations and price targets on shares of Humana (NYSE: HUM) in the last few weeks:

  • 8/8/2018 – Humana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of Humana have outperformed its industry’s growth year to date. Moreover, the company has witnessed its 2018 and 2019 earnings estimates move upward over the last seven days. The insurer is well-poised for growth on its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Sufficient generation of cash flow has helped the company take up many capital deployment initiatives aimed at enhancing its shareholder value. Humana’s sound balance sheet and a disciplined capital management remain its major tailwinds. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. Following the solid second-quarter results and the buyouts of Curo Healthcare and Kindred, the company provided a bullish EPS guidance for 2018. However, its rising level of expenses persistently weighs on the bottom line.”
  • 8/2/2018 – Humana had its price target raised by analysts at Morgan Stanley from $362.00 to $365.00. They now have an “overweight” rating on the stock.
  • 8/2/2018 – Humana had its “hold” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $350.00 price target on the stock.
  • 8/2/2018 – Humana had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $318.00 price target on the stock.
  • 8/2/2018 – Humana had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $355.00 price target on the stock.
  • 8/2/2018 – Humana had its price target raised by analysts at Bank of America Corp from $338.00 to $375.00. They now have a “buy” rating on the stock.
  • 8/2/2018 – Humana had its price target raised by analysts at Jefferies Financial Group Inc from $356.00 to $372.00. They now have a “buy” rating on the stock.
  • 7/12/2018 – Humana is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $362.00 price target on the stock.
  • 7/6/2018 – Humana had its price target raised by analysts at Piper Jaffray Companies from $326.00 to $350.00. They now have an “overweight” rating on the stock.
  • 7/4/2018 – Humana was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 6/25/2018 – Humana had its price target raised by analysts at BMO Capital Markets from $328.00 to $355.00. They now have an “outperform” rating on the stock.

Shares of HUM stock opened at $324.62 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana Inc has a fifty-two week low of $231.90 and a fifty-two week high of $331.09. The stock has a market capitalization of $44.78 billion, a price-to-earnings ratio of 27.72, a PEG ratio of 1.62 and a beta of 0.93.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The company had revenue of $14.26 billion for the quarter, compared to analyst estimates of $14.16 billion. During the same period in the prior year, the firm posted $3.49 EPS. equities research analysts expect that Humana Inc will post 14.18 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, September 27th. Humana’s payout ratio is currently 17.08%.

In other Humana news, insider Elizabeth D. Bierbower sold 6,036 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $300.91, for a total value of $1,816,292.76. Following the transaction, the insider now directly owns 21,683 shares of the company’s stock, valued at approximately $6,524,631.53. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider William Kevin Fleming sold 15,637 shares of the company’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $293.08, for a total value of $4,582,891.96. Following the completion of the transaction, the insider now directly owns 15,650 shares in the company, valued at $4,586,702. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 108,068 shares of company stock worth $33,185,697. Insiders own 0.60% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Synovus Financial Corp acquired a new position in shares of Humana during the 1st quarter valued at about $100,000. Sun Life Financial INC increased its holdings in shares of Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after acquiring an additional 204 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in shares of Humana during the 1st quarter valued at about $113,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 388 shares during the last quarter. Finally, Stratos Wealth Partners LTD. increased its holdings in shares of Humana by 448.7% during the 1st quarter. Stratos Wealth Partners LTD. now owns 417 shares of the insurance provider’s stock valued at $112,000 after acquiring an additional 341 shares during the last quarter. 93.40% of the stock is currently owned by institutional investors.

Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.

Featured Article: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.